Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab

• Sponsor: University of Sao Paulo (Other)
• Overall Status: Completed
• CT.gov ID: NCT00804921
• Collaborator: (none)
• Location: 1

Study Details

Study Description

Brief Summary

Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV).

Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.

Condition or Disease	Intervention/Treatment	Phase
Macular Edema; Diabetic Retinopathy; Macular Degeneration	Drug: bevacizumab; Procedure: anterior chamber paracentesis; Drug: acetazolamide; Drug: brimonidine	Phase 2

Study Design

• Study Type: Interventional
• Official Title: Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results

Outcome Measures

Primary Outcome Measures

1. Intra-ocular pressure variation after intra-vitreous injection of bevacizumab []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 50 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• macular edema

Exclusion Criteria:

• pulmonary chronic problems

• chronic renal failure

• intraocular inflammation

• drug or alcohol addiction

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	School of Medicine - Clinical Hospital	Ribeirao Preto	SP	Brazil	14049-900

Sponsors and Collaborators

• University of Sao Paulo

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00804921
• Other Study ID Numbers: IOP After Bevacizumab
• First Posted: Dec 9, 2008
• Last Update Posted: Dec 9, 2008
• Last Verified: Dec 1, 2008

• Keywords provided by , ,: bevacizumab; intra-ocular pressure; acetazolamide; anterior chamber paracentesis; brimonidine; macular edema secondary to diabetic retinopathy or macular degeneration
• Additional relevant MeSH terms: Macular Degeneration; Macular Edema; Retinal Diseases; Diabetic Retinopathy; Bevacizumab; Brimonidine Tartrate; Acetazolamide

Study Results

No Results Posted as of Dec 9, 2008